Società Bristol-Myers Squibb Company Buenos Aires S.E.

BMY

ARDEUT112877

Prodotti farmaceutici

Consensus Analisti

Attività

Vendite per attività

Vendite per regione

Dirigenti

Amministratori

Classe di azioni

Azionisti

Partecipazioni

Coordinate società

Società del gruppo

Settore

Vendite per regione

Rating per Bristol-Myers Squibb Company

Revisioni EPS

Utili trimestrali - Indice di sorpresa

Settore Prodotti farmaceutici - Altri

Prezzo di chiusura Buenos Aires S.E. Altri mercati azionari 00:00:00 31/05/2024			Variaz. 5gg	Var. 1 gen.
17.023 ^ARS	+4,01%		+0,57%	+3,44%

30/05	Bristol-Myers Squibb dichiara che Breyanzi ottiene l'approvazione della FDA come terapia a cellule T CAR per il linfoma a cellule del mantello	MT
30/05	La FDA statunitense autorizza l'uso della terapia cellulare di Bristol per un raro tumore del sangue	RE

Bristol-Myers Squibb Company è specializzata nello sviluppo, nella produzione e nella commercializzazione di prodotti farmaceutici. I prodotti sono destinati al trattamento dei tumori, delle malattie cardiovascolari, dell'epatite, delle malattie immunitarie e dei disturbi psichiatrici.
Gli Stati Uniti rappresentano il 70,1% delle vendite nette.

Numero di dipendenti: 34 100

USD in Milioni	2022	Peso	2023	Peso	Delta
Innovative Medicines 100,0 %	46 159	100,0 %	45 006	100,0 %	-2,50%

USD in Milioni	2022	Peso	2023	Peso	Delta
United States 70,1 %	31 828	69,0 %	31 555	70,1 %	-0,86%
International 28,3 %	13 497	29,2 %	12 752	28,3 %	-5,52%
Other 1,6 %	834	1,8 %	699	1,6 %	-16,19%

Dirigenti	Titolo	Età	Da
Christopher Boerner CEO	Chief Executive Officer	53	01/02/15
David Elkins DFI	Director of Finance/CFO	55	20/11/19
Greg Meyers CTO	Chief Tech/Sci/R&D Officer	-	-
Kimberly McCutcheon Jablonski CMP	Compliance Officer	-	01/01/03
Estelle Vester-Blokland CTO	Chief Tech/Sci/R&D Officer	-	-
Samit Hirawat CTO	Chief Tech/Sci/R&D Officer	55	01/01/19
Robert Plenge CTO	Chief Tech/Sci/R&D Officer	53	01/11/19
Laura Hortas IRO	Public Communications Contact	-	-
Cynthia Piccirillo PRN	Corporate Officer/Principal	-	-
Cari Gallman PRN	Corporate Officer/Principal	-	-

Amministratori	Titolo	Età	Da
Phyllis Yale BRD	Director/Board Member	66	20/11/19
Peter Arduini BRD	Director/Board Member	59	01/04/16
Derica Rice BRD	Director/Board Member	59	01/09/20
Paula Price BRD	Director/Board Member	62	01/09/20
Theodore Samuels BRD	Director/Board Member	69	21/02/17
David Elkins DFI	Director of Finance/CFO	55	20/11/19
Christopher Boerner CEO	Chief Executive Officer	53	01/02/15
Julia Haller BRD	Director/Board Member	69	20/11/19
Karen Vousden BRD	Director/Board Member	66	01/01/18
Manuel Hidalgo Medina BRD	Director/Board Member	56	01/06/21

	Voto	Quantità	Flottante	Autocontrollo	Flottante totale
Azione A	1	2 923 100 096	2 024 918 592 ( 69,27 %)	896 000 000 ( 30,65 %)	69,27 %

Nome	Azioni	%	Valorizzazione
Vanguard Fiduciary Trust Co. 9,181 %	186 067 109	9,181 %	8 317 M $
BlackRock Advisors LLC 6,185 %	125 355 772	6,185 %	5 603 M $
STATE STREET CORPORATION 4,518 %	91 571 110	4,518 %	4 093 M $
JPMorgan Investment Management, Inc. 4,368 %	88 525 438	4,368 %	3 957 M $
Capital Research & Management Co. (International Investors) 3,464 %	70 203 814	3,464 %	3 138 M $
Charles Schwab Investment Management, Inc. 2,650 %	53 715 966	2,650 %	2 401 M $
Fidelity Management & Research Co. LLC 2,100 %	42 557 702	2,100 %	1 902 M $
Geode Capital Management LLC 2,038 %	41 304 605	2,038 %	1 846 M $
BlackRock Life Ltd. 1,574 %	31 893 511	1,574 %	1 426 M $
Norges Bank (13F) 1,501 %	30 413 639	1,501 %	1 359 M $

Nome	Azioni	%	Valorizzazione
Bram Bradesco Asset Management S/A DTVM 0,000233 %	4 731	0,000233 %	209 518 $

Nome	Azioni	%	Valorizzazione
Transcend Wealth Collective LLC -	117 775	-	7 184 $
FourWorld Capital Management LLC -	100 000	-	6 100 $
Davenport & Co. LLC -	83 970	-	5 122 $
CapFinancial Partners LLC -	20 498	-	1 250 $
FIFTH THIRD BANCORP -	20 000	-	1 220 $
Private Advisor Group LLC -	15 000	-	915 $
Paradigm Financial Partners LLC -	10 000	-	610 $
Northwestern Mutual Wealth Management Co. -	242	-	15 $
OAKWORTH CAPITAL INC. -	125	-	8 $
Atlantic Edge Private Wealth Management LLC -	16	-	1 $

Nome	Azioni	%	Valorizzazione
AVIDITY BIOSCIENCES, INC. 5.31%	5 075 304	5.31%	120 944 494 $
AVIDITY BIOSCIENCES, INC. 6.36%	759 145	6.36%	21 438 255 $
COMPUGEN LTD. 5.31%	4 757 058	5.31%	9 546 749 $
CELULARITY INC. 5.49%	1 195 327	5.49%	3 669 654 $

Bristol Myers Squibb Co.

Route 206 & Province Line Road

08543, Princeton

+609 252 4621

http://www.bms.com

Indirizzo Bristol-Myers Squibb Company(BMY)

Nome	Categoria e settore
Bristol-Myers Squibb India Pvt Ltd. Bristol-Myers Squibb India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb India Pvt Ltd. discovers, develops and delivers medicines for immuno-oncology. The company is based in Mumbai, India.	Pharmaceuticals: Major
Bristol-Myers Squibb de México S de RL de CV Bristol-Myers Squibb de México S de RL de CV Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb de México S de RL de CV is a Mexican company that manufactures and supplies pharmaceutical and nutritional products. The company is located in Mexico.	Pharmaceuticals: Major
Celgene Kappa Holdings LLC
Bristol-Myers Squibb International Co. ULC
Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH
Seamair Insurance DAC
Bristol-Myers Squibb AE
Swords Laboratories Unlimited Co. Swords Laboratories Unlimited Co. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Swords Laboratories Unlimited Co. is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Swords, Ireland.	Pharmaceuticals: Major
BMS Strategic Portfolio Investments Holdings, Inc.
Bristol-Myers Squibb (Finland) Oy Ab Bristol-Myers Squibb (Finland) Oy Ab Pharmaceuticals: GenericHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb (Finland) Oy Ab is a Finnish pharmaceutical manufacturing company. The company is based in Vantaa, Finland. The company was founded in 1974. Simone Böhrer has been the CEO of the company since 2020.	Pharmaceuticals: Generic
Celgene Alpine Investment Co. LLC
Bristol-Myers Squibb SARL Bristol-Myers Squibb SARL Medical DistributorsDistribution Services Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France.	Medical Distributors
Celgene Alpine Investment Co. III LLC Celgene Alpine Investment Co. III LLC Financial ConglomeratesFinance Part of Bristol Myers Squibb Co., Celgene Alpine Investment Co. III LLC is an American company that provides investment services. The company is located in the US.	Financial Conglomerates
Westwood-Intrafin SA
BMS Forex Co.
Bristol-Myers Squibb GmbH & Co. KGaA Bristol-Myers Squibb GmbH & Co. KGaA Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb GmbH & Co. KGaA is a German company that manufactures biopharmaceutical medicines. The company is based in Munich, Germany. The CEO of the company is Han Steutel.	Pharmaceuticals: Major
Bristol-Myers Squibb SA (Spain)
Bristol-Myers Squibb KK Bristol-Myers Squibb KK BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb KK develops, manufactures and markets biopharmaceutical products. The company is based in Shinjuku-ku, Japan.	Biotechnology
Bristol-Myers Squibb Australia Pty Ltd. Bristol-Myers Squibb Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Australia Pty Ltd. is a biopharmaceutical company that researches, develops and markets medicines for serious diseases. The company was founded in 1930 and is headquartered in Noble Park North, Australia.	Pharmaceuticals: Major
Bristol-Myers Squibb Belgium SA Bristol-Myers Squibb Belgium SA Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Belgium SA develops, manufactures and distributes medicines. The company is based in Watermael-Boitsfor, Belgium. The CEO of the Belgian company is Paul Lacante.	Pharmaceuticals: Major
Bristol-Myers Squibb SRL Bristol-Myers Squibb SRL Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb SRL develops, manufactures and supplies pharmaceuticals. It offers diabetes, oncology, cardiovascular, neuroscience, virology, and immunology services. The company is headquartered in Rome, Italy.	Pharmaceuticals: Major
Bristol-Myers Squibb Pharmaceuticals Unlimited Co.
Bristol-Myers Squibb Canada Co. Bristol-Myers Squibb Canada Co. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Canada Co. designs, develops and wholesales pharmaceutical products. The company is headquartered in Halifax, Canada.	Pharmaceuticals: Major
Bristol-Myers Squibb Holdings Ireland Unlimited Co. Bristol-Myers Squibb Holdings Ireland Unlimited Co. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Holdings Ireland Unlimited Co., a subsidiary of Bristol Myers Squibb Co., is a company headquartered in Ireland that operates as a holding company which develops medicines for serious diseases.	Pharmaceuticals: Major
JUNO THERAPEUTICS INC	Biotechnology
Bristol-Myers Squibb Pharmaceuticals Ltd. Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK.	Pharmaceuticals: Major
Bristol-Myers Squibb AB Bristol-Myers Squibb AB Medical DistributorsDistribution Services Part of Bristol Myers Squibb Co., Bristol-Myers Squibb AB is a company that wholesales medical equipment and pharmacy. The company is based in Solna, Sweden.	Medical Distributors
Bristol-Myers Squibb SA (Switzerland)

Rating Trading

Rating Investimento

ESG Refinitiv

Altri rating

Vendita

Buy

Raccomandazione media

Hold

Numero di analisti

Ultimo prezzo di chiusura

41,09 USD

Prezzo obiettivo medio

53,19 USD

Differenza / Target Medio

+29,46%

Consenso

Revisioni delle Stime

Calendario della società

Biotecnologia/Farmaceutici

Biotecnologia/Farmaceutici

Prodotti farmaceutici

Prodotti farmaceutici - Altri

	Variaz. 1 gen.	Capi.
ELI LILLY AND COMPANY	+40,73%	739 Mrd
NOVO NORDISK A/S	+32,83%	598 Mrd
JOHNSON & JOHNSON	-6,30%	353 Mrd
MERCK & CO., INC.	+15,15%	318 Mrd
ABBVIE INC.	+4,05%	285 Mrd
ASTRAZENECA PLC	+15,00%	240 Mrd
NOVARTIS AG	+9,78%	210 Mrd
ROCHE HOLDING AG	-5,52%	206 Mrd
AMGEN INC.	+6,17%	164 Mrd

Prodotti farmaceutici - Altri